[Addition of docetaxel to hormonal therapy in low- and high-burden metastatic hormone sensitive prostate cancer: long-term survival results from the STAMPEDE trial].

[Addition of docetaxel to hormonal therapy in low- and high-burden metastatic hormone sensitive prostate cancer: long-term survival results from the STAMPEDE trial]. Urologe A. 2020 Apr 02;: Authors: von Amsberg G PMID: 32240319 [PubMed - as supplied by publisher]

https://www.ncbi.nlm.nih.gov/pubmed/32240319?dopt=Abstract

Source: Der Urologe. Ausg. A - April 1, 2020 Category: Urology & Nephrology Authors: von Amsberg G Tags: Urologe A Source Type: research